Transparency Market Research

Chemotherapy Induced Nausea and Vomiting (CINV) Existing and Pipeline Drugs Market Expected to Reach USD 1.88 Billion Globally in 2020

CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020


Albany, NY -- (SBWIRE) -- 06/09/2015 -- According to a new market report published by Transparency Market Research "CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020," the global CINV drugs market was valued at USD 1.28 billion in 2013 and is expected to grow at a CAGR of 5.7% from 2014 to 2020, to reach an estimated value of USD 1.88 billion in 2020.

Browse the full CINV Existing and Pipeline Drugs Market Report at

Chemotherapy induced nausea and vomiting (CINV) refers to nausea and vomiting associated with cancer chemotherapy. CINV is one of the most common side effects experienced by cancer patients undergoing chemotherapy. Although there are currently several drugs available to manage CINV, this side effect continues to be a major concern for patients and oncologists associated with chemotherapy. Companies such as Helsinn Holding S.A., Heron Therapeutics, Inc. and Tesaro, Inc. are striving to develop new and more efficacious therapeutic solutions to treat CINV.


Aloxi (palonosetron), Zofran (ondansetron), Kytril (granisetron) and Emend (aprepitant) are the major available drugs which are used to manage CINV. Recently in October 2014, U.S. FDA approved the first fixed combination oral agent, Akynzeo (developed by Helsinn Holding S.A.) for the prevention of CINV. Akynzeo, being the first fixed-dose combination providing patients with two antiemetics in a single dose, is likely to offer better patient compliance and consequently is expected to witness increasing popularity among physicians.

SUSTOL (APF-530) and rolapitant are the two major CINV pipeline drugs that are currently under phase III or registration phase and would be introduced in the near future. Approval of these two pipeline drugs will be driving the overall CINV drugs market during the forecast period from 2014 to 2020. In addition to this, continuous increase in number of patients undergoing chemotherapy is also expected to play a key role in the growth of CINV drugs market. Various sources indicate that approximately 70% to 80% cancer patients on chemotherapy exhibit nausea and vomiting as major side effects.

Two key CINV drugs Aloxi and Emend are going off-patent in 2015, post which a number of generic manufacturers are likely to enter in the market with generic versions of these two brands. Therefore, patent expiry of Aloxi and Emend has been anticipated to affect market revenue during the forecast period, as their generic versions will be sold at 80% to 85% lower prices than the branded ones.

Browse the full Press Release Report :

Geographically, North America was the largest regional market for CINV drugs in 2013 with a market share of over 45% of the total revenue generated globally, followed by Europe. North America it is expected to retain its leading position through 2020, growing at a CAGR of more than 7% during the forecast period from 2014 to 2020. On the other hand, the CINV drugs market in Asia-Pacific would be primarily driven by the increasing penetration of western companies coupled with the growing number of cancer patients. In many countries in Asia-Pacific and Rest of the World (RoW) regions, generic manufacturers would be competing with the branded CINV drug manufacturers. Owing to the low purchasing power of people, generic versions of expired branded drugs are in greater demand in the region.

GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, Inc. are some of the key players actively participating in the CINV drugs market.

The global CINV existing and pipeline drugs market is segmented as follows:

CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Major Drugs
Aloxi (palonosetron)
Zofran Generic (ondansetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
SUSTOL (extended release granisetron injection)
CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Geography
North America
Rest of the World (RoW)

Request a Brochure of this Report:

About Transparency Market Research
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453